Plain-English translation of NCT06143553 on ClinicalTrials.gov ↗ ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is comparing a new way of giving paclitaxel—called —against standard chemotherapy options that your doctor might choose for you. You're eligible if you have advanced breast cancer that has spread, your tumors are HER2-negative, and you've already tried at least two previous chemotherapy treatments. The study will track how long the cancer stays under control and how safe the medication is.
Patients with advanced breast cancer who have already received multiple rounds of chemotherapy often have limited options, and their cancer may become resistant to standard treatments. This trial is testing whether this new formulation of paclitaxel might help these patients live longer before their cancer progresses, compared to other chemotherapy choices currently available.
If you join this trial, you will be randomly assigned to receive either the new paclitaxel polymeric micelles treatment or one of several standard chemotherapy options that your doctor would choose for you. The new treatment is given as an intravenous infusion once every 3 weeks, while the control treatments vary but are given on similar schedules. You will continue treatment for at least 6 cycles (about 18 weeks), and possibly longer, until your cancer progresses, you develop severe side effects, or you decide to stop—with regular monitoring visits to track how you're responding.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China